According to the Federal Act on Narcotics and Psychotropic Substances, the cannabis plant and its derivatives with a higher or equivalent THC content of 1% are not allowed in Switzerland. However, there is a significant amount of hemp products with low THC content. These are not subject to the Narcotics Act, as their THC content is less than 1%. Today, there are products based on raw materials such as flowers or cannabis powder on the market. In addition, there are also processed products such as extracts in the form of paste or oil, tobacco substitutes, sweets, chewing gums, liquids for e-cigarettes, food supplements, essential oils and ointments. You can also make paper, clothes, various fabrics, ropes and even insulation for buildings.


In cannabis there are about 80 cannabinoids and more than 400 other substances. The two most important are THC, tetrahydrocannabinol, and CBD, cannabidiol. The latter diminishes, among other things, the psychotropic effect of THC. CBD is not subject to the Narcotics Act.

Products with a high amount of CBD and a low THC content are those that are gaining more and more importance. There is strong demand and supply is expanding at an impressive rate. The likely therapeutic effects (antipsychotics, antioxidants, anxiolytics, anti-inflammatories, antiemetics, anticonvulsants) are still debated. For now, studies on the medical effects of cannabidiol are not enough.

For more information :

Federal law on tobacco taxation

Regulation on tobacco products and products containing tobacco alternatives with the purpose of smoking

Swissmedic (Overview of products containing CBD)

Regulation of the DFI on Narcotic Drugs and Psychotropic Substances

Federal Act on Narcotics and Psychotropic Substances

Swiss addiction’s CBD fact sheet

Source :